公开(公告)号：US20160243225A1

公开(公告)日：2016-08-25

申请号：US15026460

申请日：2014-10-17

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Ella IOFFE ,  Israel LOWY ,  Gavin THURSTON ,  Elena BUROVA

IPC: A61K39/395 ,  C07K16/22 ,  C07K14/71 ,  A61K9/00 ,  C07K16/28 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K38/179 ,  A61K38/1793 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/71 ,  C07K16/22 ,  C07K16/2818 ,  C07K16/2863 ,  C07K2317/76 ,  C07K2319/30 ,  A61K2300/00

Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.

Abstract translation: 本发明提供包含VEGF拮抗剂和抗CTLA-4抗体的药物组合物及其使用方法。 本发明的组合物和方法可用于治疗其中抗血管生成疗法和/或靶向免疫应答可能是有益的癌症和其它疾病和病症。

公开(公告)号：US20130344093A1

公开(公告)日：2013-12-26

申请号：US13925923

申请日：2013-06-25

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Christopher DALY ,  Gavin THURSTON ,  Nicholas J. PAPADOPOULOS

IPC: A61K39/395

CPC classification number: A61K39/39558 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.